[go: up one dir, main page]

LT4153136T - Osmosinės vaisto formos, apimančios deutetrabenaziną ir jo vartojimo būdai - Google Patents

Osmosinės vaisto formos, apimančios deutetrabenaziną ir jo vartojimo būdai

Info

Publication number
LT4153136T
LT4153136T LTEPPCT/US2021/036778T LTUS2021036778T LT4153136T LT 4153136 T LT4153136 T LT 4153136T LT US2021036778 T LTUS2021036778 T LT US2021036778T LT 4153136 T LT4153136 T LT 4153136T
Authority
LT
Lithuania
Prior art keywords
deutetrabenazine
methods
dosage forms
osmotic dosage
osmotic
Prior art date
Application number
LTEPPCT/US2021/036778T
Other languages
English (en)
Inventor
Parag Shah
Mayank Joshi
Soumen PATTANAYEK
Divyang PATEL
Sandeep Pandita
Original Assignee
Auspex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals, Inc. filed Critical Auspex Pharmaceuticals, Inc.
Publication of LT4153136T publication Critical patent/LT4153136T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4747Quinolines; Isoquinolines spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2021/036778T 2020-06-10 2021-06-10 Osmosinės vaisto formos, apimančios deutetrabenaziną ir jo vartojimo būdai LT4153136T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063037369P 2020-06-10 2020-06-10
US202063037953P 2020-06-11 2020-06-11
US202063044451P 2020-06-26 2020-06-26
PCT/US2021/036778 WO2021252741A1 (en) 2020-06-10 2021-06-10 Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Publications (1)

Publication Number Publication Date
LT4153136T true LT4153136T (lt) 2024-03-25

Family

ID=78826343

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2021/036778T LT4153136T (lt) 2020-06-10 2021-06-10 Osmosinės vaisto formos, apimančios deutetrabenaziną ir jo vartojimo būdai

Country Status (26)

Country Link
US (3) US11311488B2 (lt)
EP (2) EP4153136B1 (lt)
JP (2) JP7419571B2 (lt)
KR (2) KR20240025706A (lt)
CN (1) CN115916154A (lt)
AU (3) AU2021288087B2 (lt)
BR (1) BR112022025185B1 (lt)
CA (1) CA3186425A1 (lt)
CL (1) CL2022003512A1 (lt)
DK (1) DK4153136T3 (lt)
ES (1) ES2975960T3 (lt)
FI (1) FI4153136T3 (lt)
HR (1) HRP20240303T1 (lt)
HU (1) HUE065723T2 (lt)
IL (1) IL298629A (lt)
LT (1) LT4153136T (lt)
MX (1) MX2022015742A (lt)
PE (1) PE20230852A1 (lt)
PL (1) PL4153136T3 (lt)
PT (1) PT4153136T (lt)
RS (1) RS65328B1 (lt)
SI (1) SI4153136T1 (lt)
SM (1) SMT202400118T1 (lt)
TW (1) TW202214246A (lt)
WO (1) WO2021252741A1 (lt)
ZA (1) ZA202213478B (lt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250019144A (ko) * 2022-06-08 2025-02-07 오스펙스 파마슈티칼스, 인코포레이티드 듀테트라베나진을 포함하는 삼투성 제형 및 이의 사용 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
US20070031496A1 (en) * 2005-08-04 2007-02-08 Edgren David E Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
US8524733B2 (en) 2008-09-18 2013-09-03 Auspex Pharmaceuticals Benzoquinoline inhibitors of vesicular monoamine transporter 2
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル(バルバドス)エスアールエル 医薬組成物
IN2015DN01662A (lt) * 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc
JP6932641B2 (ja) * 2015-03-06 2021-09-08 オースペックス ファーマシューティカルズ インコーポレイテッド 異常不随意運動障害の処置のための方法
WO2017182916A1 (en) * 2016-04-22 2017-10-26 Lupin Limited Novel process for preparation of tetrabenazine and deutetrabenazine
US20170312226A1 (en) * 2016-04-28 2017-11-02 Ascent Pharmaceuticals, Inc. Pharmaceutical dosage forms
PE20191819A1 (es) * 2017-03-15 2019-12-27 Auspex Pharmaceuticals Inc Analogos de deutetrabenazina, su preparacion y uso
US20190099377A1 (en) * 2017-10-02 2019-04-04 Powder Pharma Coating Inc. Method for dry powder coating osmotic drug delivery system
WO2019173384A1 (en) * 2018-03-05 2019-09-12 Kashiv Pharma Llc Programmable pharmaceutical compositions for chrono drug release
MA53239A (fr) * 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2

Also Published As

Publication number Publication date
EP4364738A3 (en) 2024-06-19
SI4153136T1 (sl) 2024-05-31
JP7419571B2 (ja) 2024-01-22
JP2024058686A (ja) 2024-04-26
IL298629A (en) 2023-01-01
AU2021288087A1 (en) 2023-01-19
PT4153136T (pt) 2024-03-22
EP4364738A2 (en) 2024-05-08
ZA202213478B (en) 2025-03-26
DK4153136T3 (da) 2024-03-25
SMT202400118T1 (it) 2024-05-14
TW202214246A (zh) 2022-04-16
PE20230852A1 (es) 2023-05-29
KR102638424B1 (ko) 2024-02-19
AU2021288087B2 (en) 2023-03-30
US20240307313A1 (en) 2024-09-19
ES2975960T3 (es) 2024-07-18
EP4153136B1 (en) 2024-01-10
KR20230016703A (ko) 2023-02-02
AU2023204103B2 (en) 2025-08-14
RS65328B1 (sr) 2024-04-30
CN115916154A (zh) 2023-04-04
PL4153136T3 (pl) 2024-06-24
HUE065723T2 (hu) 2024-06-28
BR112022025185B1 (pt) 2023-10-24
US11311488B2 (en) 2022-04-26
MX2022015742A (es) 2023-01-19
US20210386673A1 (en) 2021-12-16
HRP20240303T1 (hr) 2024-05-10
FI4153136T3 (fi) 2024-03-19
WO2021252741A1 (en) 2021-12-16
CL2022003512A1 (es) 2023-07-28
BR112022025185A2 (pt) 2022-12-27
JP2023523092A (ja) 2023-06-01
CA3186425A1 (en) 2021-12-16
JP7769731B2 (ja) 2025-11-13
KR20240025706A (ko) 2024-02-27
US20230022862A1 (en) 2023-01-26
AU2025205457A1 (en) 2025-07-31
EP4153136A1 (en) 2023-03-29
AU2023204103A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
IL281082A (en) Preparations of CXCR4 inhibitors and methods of preparation and use
SG11202107614PA (en) Pcsk9 inhibitors and methods of use thereof
SG11202107615TA (en) Pcsk9 inhibitors and methods of use thereof
IL287751A (en) kcnt1 inhibitors and methods of use
IL287768A (en) kcnt1 inhibitors and methods of use
IL286248A (en) Tyk2 inhibitors and uses thereof
IL292810A (en) Therapeutic compounds and methods of use
IL287973A (en) acss2 inhibitors and methods of their use
IL279475A (en) Actonucleotidase inhibitors and methods of using them
ZA202400656B (en) 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof
IL267344A (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
IL299245A (en) LAIR-1 binding agents and methods of using them
IL267503A (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
GB202306894D0 (en) Therapeutic and prohylactic use of microoganisms
IL264854A (en) Spt5 inhibitors and methods of use thereof
SG11202110545TA (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
IL280453B1 (en) History of benzenesulfonamide-phenyl-alkyloxy-alkyl acids and their use in therapy.
ZA201903828B (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
IL299104A (en) Intracellular administration of a CEBP antagonist and methods of use
SI4153136T1 (sl) Osmotske dozirne oblike, ki vsebujejo devtetrabenazin in načini njihove uporabe
IL286149A (en) Caspase inhibitors and methods of using them
IL276792A (en) Inhaler and methods for using it
IL317235A (en) Osmotic dosage forms comprising ditetrabenzene and methods of using the same
HK40120984A (zh) 包含氘代丁苯那嗪的渗透剂型及其使用方法
HK40123899A (en) Osmotic dosage forms comprising deutetrabenazine and methods of use thereof